ABVC BioPharma, Inc. (NASDAQ:ABVC – Get Free Report) saw a large drop in short interest in January. As of January 31st, there was short interest totalling 220,000 shares, a drop of 25.0% from the January 15th total of 293,400 shares. Currently, 2.0% of the company’s stock are short sold. Based on an average daily volume of 197,200 shares, the short-interest ratio is presently 1.1 days.
ABVC BioPharma Stock Performance
ABVC stock opened at $0.42 on Friday. ABVC BioPharma has a fifty-two week low of $0.40 and a fifty-two week high of $1.73. The company’s 50 day moving average price is $0.53 and its 200 day moving average price is $0.59. The firm has a market capitalization of $5.44 million, a price-to-earnings ratio of -0.49 and a beta of 0.67.
Institutional Trading of ABVC BioPharma
A hedge fund recently raised its stake in ABVC BioPharma stock. Avantax Planning Partners Inc. grew its stake in ABVC BioPharma, Inc. (NASDAQ:ABVC – Free Report) by 269.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 143,968 shares of the company’s stock after buying an additional 104,968 shares during the period. Avantax Planning Partners Inc. owned 1.11% of ABVC BioPharma worth $85,000 at the end of the most recent reporting period. 11.38% of the stock is owned by institutional investors and hedge funds.
About ABVC BioPharma
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.
Recommended Stories
- Five stocks we like better than ABVC BioPharma
- What is the FTSE 100 index?
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Where Do I Find 52-Week Highs and Lows?
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Breakout Stocks: What They Are and How to Identify Them
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
